Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18020267 | 0.82 | MAOA (0.39) | MAOAMAOBGAANPSR1NPC1 | |
| SCHEMBL19821005 | 0.78 | MAOA (0.36) | MAOAMAOBGAANPSR1NPC1 | |
| SCHEMBL7385496 | 0.77 | — | — | |
| SCHEMBL17058245 | 0.77 | — | — | |
| SCHEMBL1320655 | 0.72 | MAOA (0.39) | MAOAMAOBGAANPSR1ALOX5 | |
| SCHEMBL4233622 | 0.69 | CES1 (0.32) | MAOAMAOBNPC1LMNARAB9A | |
| SCHEMBL255955 | 0.67 | ABCG2 (0.39) | MAOAMAOBLMNASMN1; SMN2 | |
| Xanthene SCHEMBL30586075 | 0.67 | MAOA (1.00) | MAOAMAOBGAANPSR1NPC1 | |
| SCHEMBL30360775 | 0.67 | MAOA (0.70) | MAOAMAOBGAANPSR1NPC1 | |
| Xanthene SCHEMBL29378346 | 0.67 | MAOA (1.00) | MAOAMAOBGAANPSR1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3256468-B1 | TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO LTD (CN) | 2020-04-08 | — | — | EP | disclosed |
| US-10183917-B2 | Tricyclic compounds and uses thereof in medicine | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2019-01-22 | — | — | US | disclosed |
| US-20180030003-A1 | TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030003-A1 | TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | NR1H4, SLC10A1, SLC10A2 | MAOA 1929/4885MAOB 1261/4885GAA 1436/4885 |
| US-10183917-B2 | Tricyclic compounds and uses thereof in medicine | NR1H4, SLC10A1, SLC10A2 | MAOA 1929/4885MAOB 1261/4885GAA 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.